LinkedIn Profile

Access Ionis Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
nasdaq:ions 12150 Sep 23rd, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 711.00 Open Biotechnology Sep 23rd, 2021 09:31AM Sep 23rd, 2021 09:31AM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology
nasdaq:ions 12150 Sep 22nd, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 711.00 Open Biotechnology Sep 22nd, 2021 09:03AM Sep 22nd, 2021 09:03AM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology
nasdaq:ions 12150 Sep 21st, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 711.00 Open Biotechnology Sep 21st, 2021 09:43AM Sep 21st, 2021 09:43AM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology
nasdaq:ions 12150 Sep 20th, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 709.00 Open Biotechnology Sep 20th, 2021 09:45AM Sep 20th, 2021 09:45AM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology
nasdaq:ions 12150 Sep 19th, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 709.00 Open Biotechnology Sep 19th, 2021 04:08PM Sep 19th, 2021 04:08PM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology
nasdaq:ions 12150 Sep 18th, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 708.00 Open Biotechnology Sep 18th, 2021 02:58PM Sep 18th, 2021 02:58PM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology
nasdaq:ions 12150 Sep 17th, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 707.00 Open Biotechnology Sep 16th, 2021 10:42PM Sep 17th, 2021 08:27AM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology
nasdaq:ions 12150 Sep 16th, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 707.00 Open Biotechnology Sep 16th, 2021 08:39AM Sep 16th, 2021 08:39AM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology
nasdaq:ions 12150 Sep 15th, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 707.00 Open Biotechnology Sep 15th, 2021 11:05AM Sep 15th, 2021 11:05AM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology
nasdaq:ions 12150 Sep 14th, 2021 12:00AM Ionis Pharmaceuticals, Inc. 25K 707.00 Open Biotechnology Sep 14th, 2021 09:14AM Sep 14th, 2021 09:14AM For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/. Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/. Spinraza is marketed by Biogen. Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply. Learn more about our history: https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t Attention Potential Applicants! Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/ See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf Open Antisense Drug Discovery Open 2855 Gazelle Ct Carlsbad CA US 92010 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.